Avalere Health
An Inovalon Company

Federal & State Policy

Predict Change

As the nation continues to struggle with improving outcomes, elevating quality, reducing costs, and driving value, federal and state policy activities remain core to making sound decisions for your business. Armed with policy experts and business strategists, Avalere guides organizations through the continued complexities of all aspects of healthcare public policy at both the federal and state levels. We help companies understand how changes to healthcare policy will affect coverage, access, payment, care delivery, and consumer choice. We partner with stakeholders from across the healthcare spectrum to help plan for insurance market reforms, Medicaid, Medicare Advantage, and Medicare Part D changes.

What's Your Challenge?

  • ​Policy Impact and Analysis
  • ​Policy Tracking and Monitoring
  • ​Comment Letters
  • ​Beneficiary Enrollment Trends

Complementary Products


Meet a few of our experts ready to partner with you.

All Staff

Caroline F. Pearson

Senior Vice President

Caroline F.

Caroline Pearson, Senior Vice President of Policy and Strategy, oversees the firm’s content generation across consulting services, research products, and public visibility. 

She previously led Avalere’s Health Reform & Policy Practice. In Caroline’s twelve years at the firm, she has focused on implementation of the Affordable Care Act (ACA), prescription drug pricing, and public and private insurance benefit design. She is regularly quoted in national and trade press and is a frequent presenter to audiences seeking to understand the health policy landscape. In 2009, Caroline contributed to a report, led by Senators Tom Daschle and Bob Dole at the Bipartisan Policy Center, which advanced a comprehensive, bipartisan health reform proposal.  

She graduated Magna Cum Laude from Harvard University with a B.A. in Government.

Daniel Goldberg

Senior Associate


Daniel Goldberg, Senior Associate, provides research and strategic support to health plan and pharmaceutical clients on health reform implementation and state health policy activities. In particular, he applies his expertise on policy issues related to commercial market benefit design, insurance exchanges, Medicaid managed care, and dual-eligible beneficiaries. 

Prior to joining Avalere, Daniel interned on the U.S. Senate Committee on Health, Education, Labor and Pensions providing research and legislative initiative support to Senator Harkin’s health policy team. In this role, he authored memos on congressional briefings and hearings related to health policy. He also conducted research services for the Office of the Inspector General of the U.S. Department of Health and Human Services, Memorial Hermann Hospital and MedStar Georgetown University Hospital. 

Daniel has a B.S. in Healthcare Management and Policy and a minor in Health Promotion and Disease Prevention from Georgetown University.  

Brenda Huneycutt

Vice President


Brenda Huneycutt, PhD, JD, MPH, Vice President in Avalere’s FDA Strategy and Regulatory Policy practice, advises clients on regulatory strategy and policy spanning drugs, biologics and diagnostics, and conducts due diligence assessments for clients looking to acquire or in-license products. Using her molecular biology research background, combined with her legal and public health policy training, Brenda helps clients translate technical information into clear descriptions for various audiences, and offers special expertise in regulatory strategy for FDA approval strategies involving accelerated and new pathways, including breakthrough therapy and orphan designations, and biosimilars and interchangeable biologics. 

Prior to joining Avalere, Brenda conducted research at the Genetics and Public Policy Center at Johns Hopkins University and was an Patent Attorney for Finnegan, LLP.

Brenda has a BA in Biology from the University of Delaware; a PhD in Molecular, Cellular, and Developmental Biology from the University of Colorado at Boulder; a JD from the George Washington University School of Law; and a MPH from Johns Hopkins Bloomberg School of Public Health.

Miryam Frieder

Vice President


Miryam Frieder, Vice President, leads strategic client engagements focused on health reform, medication adherence, pharmacy benefit management, and Medicare Part D. Miryam advises clients on assessing the impact of health reform and other aspects of the policy environment to inform business decisions and policy-related activities. Her clients include health plans, pharmacy benefit managers (PBMs), pharmaceutical manufacturers, foundations, and associations. Recent areas of focus include designing demonstration proposals for the Center on Medicare and Medicaid Innovation as well as payment and delivery reform approaches for dual eligibles.

Prior to joining Avalere, Miryam worked at The Lewin Group where she provided strategic consulting to health plans, hospitals, pharmaceutical manufacturers, and PBMs.

Miryam has a MBA from Columbia Business School and a MPH in Health Policy from the Mailman School of Public Health at Columbia University. Miryam graduated Phi Beta Kappa with a BA in Molecular Biology and Biochemistry from Wesleyan University.

« Back to Mobile Site